Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Sexually Transmitted Diseases|July 9, 2008
The influence of depression on sexual risk reduction and STD infection in a controlled, randomized intervention trialAlan E C Holden, Rochelle N Shain, Warren B Miller, et al.
American Journal of Obstetrics and Gynecology|September 24, 2021
Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosisAndrew T Gustin, Andrea R Thurman, Neelima Chandra, et al.
The Journal of Sexual Medicine|July 30, 2024
Safety of topical sildenafil cream, 3.6% in a randomized, placebo-controlled trial for the treatment of female sexual arousal disorderAndrea R Thurman, Isabella Johnson, Katherine A Cornell, et al.
Frontiers in Cellular and Infection Microbiology|March 30, 2022
Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal RingAndrea R Thurman, Jacques Ravel, Pawel Gajer, et al.
Acta Crystallographica. Section C, Crystal Structure Communications|July 7, 2010
N,N'-diethyl-4-nitrobenzene-1,3-diamine, 2,6-bis(ethylamino)-3-nitrobenzonitrile and bis(4-ethylamino-3-nitrophenyl) sulfoneThomas J Payne, Chad R Thurman, Hao Yu, et al.
The Review of Scientific Instruments|May 8, 2012
Demonstration of a real-time interferometer as a bunch-length monitor in a high-current electron beam acceleratorJ Thangaraj, G Andonian, R Thurman-Keup, et al.
Clinical and Translational Medicine|November 8, 2018
Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studiesTerry A Jacot, Meredith R Clark, Oluwatosin E Adedipe, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2018
Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate UsersAndrea R Thurman, Jill L Schwartz, Vivian Brache, et al.
Frontiers in Cellular and Infection Microbiology|May 8, 2023
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravirAndrea R Thurman, Louise A Ouattara, Nazita Yousefieh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 8, 2021
Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral AdministrationLouise A Ouattara, Andrea R Thurman, Terry A Jacot, et al.
Pageof 11